estrogen-receptor positive breast cancer
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0060075
Name estrogen-receptor positive breast cancer
Definition A breast cancer that is characterized by the presence of estrogen receptors.
Source DiseaseOntology.org
Alt Ids
Xrefs
Path disease disease of cellular proliferation cancer organ system cancer breast cancer estrogen-receptor positive breast cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp Dovitinib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 amp Cediranib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 amp Nintedanib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 amp Brivanib estrogen-receptor positive breast cancer no benefit detail...
PIK3CA E545K AZD8835 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA K111N AZD8835 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA mutant AZD8835 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA mutant Fulvestrant + Pictilisib estrogen-receptor positive breast cancer no benefit detail...
PIK3CA mutant Fulvestrant estrogen-receptor positive breast cancer no benefit detail...
PIK3CA act mut Capivasertib + Tamoxifen estrogen-receptor positive breast cancer predicted - sensitive detail...
PTEN inact mut Pictilisib estrogen-receptor positive breast cancer sensitive detail...
PTEN inact mut Fulvestrant + Pictilisib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 amp E7090 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA E78K PIK3CA E726K PIK3CA D939G Alpelisib + Letrozole estrogen-receptor positive breast cancer no benefit detail...
FGFR1 amp Alpelisib estrogen-receptor positive breast cancer resistant detail...
FGFR1 amp Lucitanib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 over exp PIK3CA mut Alpelisib + Lucitanib estrogen-receptor positive breast cancer sensitive detail...
RB1 loss Palbociclib estrogen-receptor positive breast cancer resistant detail...
PIK3CA P447_L455del Alpelisib + Letrozole estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA mutant Letrozole estrogen-receptor positive breast cancer predicted - sensitive detail...
RB1 mutant Palbociclib estrogen-receptor positive breast cancer predicted - resistant detail...
TP53 wild-type KRT-232 estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA H1047R Everolimus estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA act mut Palbociclib + Taselisib estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA act mut STK11 del MK2206 estrogen-receptor positive breast cancer resistant detail...
PIK3CA act mut STK11 del Ipatasertib estrogen-receptor positive breast cancer resistant detail...
PIK3CA act mut STK11 del Capivasertib estrogen-receptor positive breast cancer resistant detail...
FGFR1 W4C FGFR1 amp Lucitanib estrogen-receptor positive breast cancer predicted - sensitive detail...
ATM LOH ATM inact mut Ceralasertib + Olaparib estrogen-receptor positive breast cancer predicted - sensitive detail...
FGFR1 W4C FGFR1 amp Rogaratinib estrogen-receptor positive breast cancer no benefit detail...
FGFR2 M538I Fexagratinib estrogen-receptor positive breast cancer sensitive detail...
FGFR2 N550K Fexagratinib estrogen-receptor positive breast cancer sensitive detail...
FGFR2 K660N Fexagratinib estrogen-receptor positive breast cancer sensitive detail...
FGFR2 M538I FIIN-2 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 N550K FIIN-2 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 K660N FIIN-2 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 M538I FIIN-3 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 N550K FIIN-3 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 K660N FIIN-3 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 M538I Trametinib estrogen-receptor positive breast cancer sensitive detail...
FGFR2 N550K Trametinib estrogen-receptor positive breast cancer sensitive detail...
FGFR2 K660N Trametinib estrogen-receptor positive breast cancer sensitive detail...
FGFR2 M538I SHP099 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 N550K SHP099 estrogen-receptor positive breast cancer sensitive detail...
FGFR2 K660N SHP099 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA E545K Alpelisib + Everolimus estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA E545K Afatinib + Alpelisib estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA H1047R Alpelisib + Everolimus estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA H1047R Afatinib + Alpelisib estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA E545K AZD4573 + Palbociclib estrogen-receptor positive breast cancer sensitive detail...
PIK3CA E453K PIK3CA H1047R RLY-2608 estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA E542K RLY-2608 estrogen-receptor positive breast cancer predicted - sensitive detail...
CD274 positive Anthracycline + Cyclophosphamide + Nivolumab + Paclitaxel estrogen-receptor positive breast cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00570323 Phase II Anastrozole + Fulvestrant Anastrozole Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Completed USA 0
NCT00759642 Phase II Lapatinib Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy Terminated USA 0
NCT01027416 Phase I Tamoxifen Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients Completed USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA | GBR | FRA | ESP 0
NCT01219699 Phase I Alpelisib Alpelisib + Fulvestrant A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene Completed USA | NLD | GBR | ESP | DEU 0
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA | NLD | GBR | FRA | ESP | AUS 1
NCT01594216 Phase II Exemestane + Ruxolitinib Ruxolitinib in Estrogen Receptor Positive Breast Cancer Completed USA 0
NCT01857193 Phase Ib/II Everolimus + Exemestane + Ribociclib Exemestane + Ribociclib Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Completed USA | FRA | ESP | BEL 1
NCT01872260 Phase I Alpelisib + Letrozole Alpelisib + Letrozole + Ribociclib Letrozole + Ribociclib Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | CHE | AUS 1
NCT01990209 Phase II Orteronel Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Completed USA 0
NCT02035813 Phase II Ribociclib Eribulin DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). Completed DEU 0
NCT02049957 Phase Ib/II Fulvestrant + Sapanisertib Exemestane + Sapanisertib Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer Completed USA | FRA | BEL 0
NCT02115282 Phase III Exemestane + Goserelin Entinostat + Exemestane + Goserelin Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Active, not recruiting USA 1
NCT02219789 Phase I Fulvestrant Alisertib Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Completed USA 0
NCT02229084 Phase Ib/II Montanide ISA 51 + P10s-PADRE P10s-PADRE Vaccination of High Risk Breast Cancer Patients Completed USA 0
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Completed USA | ITA | ISR | FRA | ESP | CAN | BEL | AUT | AUS 0
NCT02340221 Phase III Fulvestrant + Taselisib Fulvestrant A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER) Terminated USA | TUR | SWE | ROU | POL | NLD | ITA | GRC | FRA | FIN | ESP | DEU | CZE | CAN | BGR | AUT | AUS 11
NCT02395627 Phase II Pembrolizumab + Tamoxifen + Vorinostat Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification Terminated USA 0
NCT02569801 Phase II GDC-0810 Fulvestrant A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy Terminated USA | GBR | ESP | DEU | AUS 1
NCT02580448 Phase Ib/II Seviteronel A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer Completed USA 0
NCT02598557 Phase II Exemestane Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer Completed USA | ITA 0
NCT02599714 Phase Ib/II Fulvestrant + Palbociclib + Vistusertib Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR) Completed USA | GBR 0
NCT02676986 Phase II Enzalutamide + Exemestane Exemestane Enzalutamide Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB) Completed USA | IRL | GBR | ESP | DEU 0
NCT02734615 Phase I Alpelisib + LSZ 102 LSZ 102 + Ribociclib LSZ 102 Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers Terminated USA | ITA | FRA | DEU | BEL 2
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Completed USA | NLD | FRA | CAN 0
NCT02820961 Phase I Entinostat + Exemestane Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer Completed USA 0
NCT02913430 Phase II Fulvestrant + Palbociclib Palbociclib + Tamoxifen Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib Completed USA 0
NCT02918084 Phase III Exemestane Anastrozole Letrozole CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (GIM10-CONSENT) Active, not recruiting ITA 0
NCT02988986 Phase II Sapanisertib + Tamoxifen TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer Completed USA 0
NCT03092635 Phase I Metformin + OPC AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy Terminated USA 0
NCT03201913 Phase I TTC-352 Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy Completed USA 0
NCT03285412 Phase II Ribociclib CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer (LEADER) Active, not recruiting USA 0
NCT03289039 Phase II Neratinib Fulvestrant + Neratinib Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer Terminated USA 0
NCT03321981 Phase II Letrozole + Zenocutuzumab Anastrozole + Zenocutuzumab Fulvestrant + Zenocutuzumab Exemestane + Zenocutuzumab Trastuzumab + Zenocutuzumab Trastuzumab + Vinorelbine + Zenocutuzumab MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer Completed USA | NLD | GBR | FRA | ESP | BEL 1
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Terminated USA | HUN | GBR | DNK | CAN | BEL | AUS 2
NCT03361800 Phase I Entinostat Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Terminated USA 0
NCT03573648 Phase II Leuprolide Avelumab + Palbociclib + Tamoxifen Avelumab + Tamoxifen Leuprolide + Palbociclib Avelumab + Leuprolide Avelumab + Leuprolide + Palbociclib Tamoxifen Goserelin Palbociclib + Tamoxifen Avelumab + Goserelin Goserelin + Palbociclib Avelumab + Goserelin + Palbociclib Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT) Active, not recruiting USA 0
NCT03584009 Phase II Fulvestrant Fulvestrant + Venetoclax A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy Terminated USA | GBR | DEU | CAN | AUS 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | NLD | GBR | FRA | FIN | ESP 0
NCT03874325 Phase II Durvalumab + Exemestane Durvalumab + Letrozole Anastrozole + Durvalumab Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer Terminated USA 0
NCT03900884 Phase I Letrozole + Palbociclib + Venetoclax Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (PALVEN) Active, not recruiting AUS 0
NCT04054752 Phase I NT-I7 Vaccine Response With NT-I7 Withdrawn USA 0
NCT04064359 Phase I MEN1309 Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors Recruiting USA | GRC | FRA | ESP | BEL 0
NCT04109066 Phase III Paclitaxel Anthracycline + Cyclophosphamide + Nivolumab Nivolumab + Paclitaxel Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer (CheckMate 7FL) Completed USA | TUR | ROU | POL | NLD | ITA | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 11
NCT04190056 Phase II Pembrolizumab + Tamoxifen Pembrolizumab + Tamoxifen + Vorinostat Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer Terminated USA 0
NCT04197999 Phase I GMI-1359 A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer Terminated USA 0
NCT04256941 Phase II Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Abemaciclib + Letrozole Anastrozole + Palbociclib Anastrozole + Ribociclib Letrozole + Ribociclib Abemaciclib + Anastrozole Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study Terminated USA 0
NCT04305834 Phase II Abemaciclib Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer Recruiting USA 0
NCT04478279 Phase Ib/II ST-101 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Active, not recruiting USA | GBR 0
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 Enzalutamide + PF-07220060 PF-07220060 Midazolam + PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) Active, not recruiting USA | SVK | GBR | CZE | ARG 3
NCT04601116 Phase III Atorvastatin The MASTER Study (MAmmary Cancer STatin ER Positive Study) Recruiting DNK 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04683679 Phase II Olaparib + Pembrolizumab Pembrolizumab A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer Recruiting USA 0
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT04789668 Phase Ib/II Bintrafusp alfa + Pimasertib Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases Terminated USA 0
NCT04802759 Phase Ib/II Abemaciclib + Giredestrant Giredestrant + Ipatasertib Giredestrant Everolimus + Giredestrant Giredestrant + Inavolisib Giredestrant + Ribociclib A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer Recruiting USA | ISR | ESP | AUS 1
NCT05020860 Phase II Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE) Recruiting USA 0
NCT05417594 Phase Ib/II AZD9574 + Trastuzumab deruxtecan AZD9574 + Datopotamab deruxtecan AZD9574 AZD9574 + Temozolomide Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) Recruiting USA | SWE | GBR | ESP | DEU | AUS 1
NCT05538572 Phase I PRT3645 A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors Completed USA 1
NCT05565417 Phase Ib/II Fruquintinib + IMT-009 IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas Active, not recruiting USA 0
NCT05627960 Phase I AG01 First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies Recruiting USA 0
NCT05642949 Phase Ib/II MHB036C Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05696626 Phase III Abemaciclib + Fulvestrant Abemaciclib + Lasofoxifene Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII) Recruiting USA | TUR | ROU | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT05703555 Phase II SAR408701 INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (INTRUSION) Withdrawn NLD 0
NCT05720117 Phase I PYX-201 Study of PYX-201 in Solid Tumors Recruiting USA | GBR | ESP | BEL 0
NCT05768139 Phase Ib/II Exemestane + Ribociclib + STX-478 Exemestane + Palbociclib + STX-478 Anastrozole + Ribociclib + STX-478 Anastrozole + Palbociclib + STX-478 Letrozole + Ribociclib + STX-478 Letrozole + Palbociclib + STX-478 Fulvestrant + Ribociclib + STX-478 Fulvestrant + Palbociclib + STX-478 Fulvestrant + STX-478 STX-478 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1) Recruiting USA | NLD | ITA | IRL | FRA | ESP | DEU | BEL 1
NCT05933395 Phase II Abemaciclib + Fulvestrant Fulvestrant + Neratinib Alpelisib + Fulvestrant Everolimus + Fulvestrant Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor (GERTRUDE) Recruiting USA 0
NCT06018337 Phase III Nab-paclitaxel Paclitaxel DB-1303 Capecitabine A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) Active, not recruiting USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | ARG 3
NCT06026657 Phase Ib/II Gemcitabine + TGF-beta-imprinted NK cells Gemcitabine + Naxitamab + TGF-beta-imprinted NK cells Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFbeta-i Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer Recruiting USA 0
NCT06224673 Phase II ARX-788 ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer Not yet recruiting USA 0
NCT06263543 Phase II Sacituzumab govitecan-hziy Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC (SERIES) Recruiting USA 0
NCT06486883 Phase II Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Exemestane + Ribociclib Anastrozole + Ribociclib Exemestane + Palbociclib Letrozole + Ribociclib Abemaciclib + Exemestane Letrozole + Palbociclib Fulvestrant + Ribociclib Trastuzumab deruxtecan Abemaciclib + Letrozole Anastrozole + Palbociclib Abemaciclib + Anastrozole Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype (PONTIAC) Recruiting ITA | FRA | ESP | DEU 1
NCT06545331 Phase I Pembrolizumab + XB010 XB010 Study of XB010 in Subjects With Solid Tumors Recruiting USA | GBR 0
NCT06665178 Phase II Sacituzumab govitecan-hziy Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer Recruiting CAN 0
NCT06680596 Phase II Trastuzumab deruxtecan Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy (SAFIR3LibHERty) Enrolling by invitation FRA 0
NCT06999187 Phase I DR-0202 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas Recruiting USA 0
NCT07030712 Phase I MK-8294 A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) Recruiting USA | NLD | ISR 0
NCT07112053 Phase II Capecitabine + STEMVAC STEMVAC A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Recruiting USA 0
NCT07137416 Phase I CX-5461 + Trastuzumab deruxtecan Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Recruiting USA 0
NCT07205822 Phase III Datopotamab deruxtecan A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer (TB06) Recruiting USA | ITA | FRA | ESP 2
NCT07460752 Phase II Goserelin Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients Not yet recruiting USA 0